<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1151">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03091894</url>
  </required_header>
  <id_info>
    <org_study_id>3-2017-021</org_study_id>
    <nct_id>NCT03091894</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Added to Propofol for Drug Induced Sleep Endoscopy</brief_title>
  <official_title>Dexmedetomidine Added to Propofol for Drug Induced Sleep Endoscopy: A Prospective Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Essam Fathi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      studying the effect of adding dexmedetomidine intravenous infusion to propofol intravenous
      infusion during sedation for drug induced sleep endoscopy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the current study 50 adult patients with obstructive sleep apnea were randomly allocated
      into one of two groups. Propofol group (25 patients) received only propofol
      infusion.Propofol-dex. group (25 patients) received dexmedetomidine intravenous infusion in
      addition to propofol infusion. the success of the sedation during drug induced sleep
      endoscopy was the primary outcome. The secondary outcomes were the sedation level as
      evaluated by Modified observer's assessment of alertness sedation(OAA/S) score

      , the time until sufficient sedation, the total endoscopy time,the incidence of oxygen
      desaturation and the adverse haemodynamic effects.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>success of sedation</measure>
    <time_frame>the duration of the procedure under sedation is usually about 30 minutes</time_frame>
    <description>to complete the procedure with diagnosis of site and degree of obstruction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time until sufficient sedation</measure>
    <time_frame>about 10-15 minutes from start of sedation</time_frame>
    <description>time till patient is ready to start endoscopy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Dexmedetomidine</condition>
  <arm_group>
    <arm_group_label>propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive only propofol intravenous infusion for sedation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propofol-dex.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive dexmedetomidine in addition to propofol intravenous infusion for sedation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>propofol intravenous infusion via syringe pump with loading dose of 0.5 mg/kg over 3 minutes then continuous infusion in a dose of 25-75 ug/kg/minute</description>
    <arm_group_label>propofol</arm_group_label>
    <arm_group_label>propofol-dex.</arm_group_label>
    <other_name>diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>dexmedetomidine intravenous infusion via syringe pump with loading dose of 0.5ug/kg over 5 minutes the continuous infusion in a dose of 0.2-0.7ug/kg/hour in addition to the propofol infusion as in propofol group</description>
    <arm_group_label>propofol-dex.</arm_group_label>
    <other_name>precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age more than 18 years

          -  patients with obstructive sleep apnea

          -  ASA 1and2

        Exclusion Criteria:

          -  patient refusal

          -  age less than 18 years

          -  morbid obesity

          -  known or suspected allergy to the studied drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>essam f abdelgalel, A.professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zagazig university-faculty of medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>essam f abdelgalel, A.professor</last_name>
    <phone>00201094248866</phone>
    <email>essamfathi1968@yahoo.com</email>
  </overall_contact>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>March 21, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Essam Fathi</investigator_full_name>
    <investigator_title>assistent professor</investigator_title>
  </responsible_party>
  <keyword>dexmedetomidine,propofol,sleep endoscopy,sedation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
